![[IPWatchdog Logo]](https://ipwatchdog.com/wp-content/themes/IPWatchdog%20-%202023/assets/images/temp/logo-small@2x.png){kind=logo}
Alexandros Nikolaidis
Founder
Niki IP Services
Alexandros Nikolaidis is a pharmaceutical chemist and intellectual property strategist with over fifteen years of experience in patent development, prosecution, and portfolio strategy. He is the founder of Niki IP Services, an independent consulting firm focused on life sciences, supplements, and pharmaceutical technologies. Alexandros has invented, drafted, and defended dozens of patents before the USPTO, with particular emphasis on improving the stability, bioavailability, and effectiveness of creatine and amino acid formulations. He is also recognized for being a pioneer on the use of inorganic nitrate in the context of athletic performance enhancement. Alexandros holds an MSc in Pharmaceutical Chemistry from the University of Florida and has passed the patent bar exam and is awaiting full registration as a patent agent. His research interests include the role of nitric oxide in human physiology and its potential correlation with COVID-19 susceptibility and outcomes.
Recent Articles by Alexandros Nikolaidis
When Trade Secret Injunctions Become Patent Noncompetes
A recent U.S. Court of Appeals for the Federal Circuit decision applying California trade secret law offers a timely reminder that published patent materials cannot easily be recast as trade secrets. In International Medical Devices, Inc. v. Cornell, the Federal Circuit reversed trade-secret liability and vacated related damages and injunctive relief after concluding that the plaintiffs had not shown protectable trade secrets under the California Uniform Trade Secrets Act.
License Fraud or Patent Law? Acorda v. Alkermes and the Jurisdictional Trap in Concealed Invalidity Disputes
In a recent ruling with significant implications for patent licensing disputes, the U.S. Court of Appeals for the Federal Circuit’s decision in Acorda Therapeutics, Inc. v. Alkermes Pharma Ireland Ltd., No. 2023-2374 (Fed. Cir. July 25, 2025), demonstrates just how critical proper jurisdictional framing is when contesting patent-related arbitration awards. The case reminds practitioners and stakeholders that even when patents sit at the heart of a dispute, the way a claim is framed can determine whether the matter will be heard by a federal court—or deflected into purely state law territory.